Further, many employers (as high as 59% of employers with at least 5,000 workers) that offered such coverage said that use of GLP-1 medications was higher than expected, and 66% of the largest employers said that covering such drugs for weight loss had a significant impact on their health plans prescription drug spending
V x l cc c t h tiu ha trc khi chng c dung np sang cc t bo khc
We typically reassess at week 4 if there's no movement at all, we look at quality of the product, technique, dose, and whether another peptide or therapy is a better fit
If the addition of GLP-1 therapy results in heart rate elevation above target ranges, increasing the beta-blocker dose (if tolerated) may be considered
We assessed heterogeneity between the included studies using the I statistic, where I 2 values of 25%, 50%, and 75% indicated low, medium, and high heterogeneity, respectively